United States - English - NLM (National Library of Medicine)

swedish orphan biovitrum ab (publ) - anakinra (unii: 9013duq28k) (anakinra - unii:9013duq28k) - anakinra 100 mg in 0.67 ml - kineret is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (ra), in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (dmards). kineret can be used alone or in combination with dmards other than tumor necrosis factor (tnf) blocking agents [see warnings and precautions (5.2)]. kineret is indicated for the treatment of neonatal-onset multisystem inflammatory disease (nomid). kineret is indicated for the treatment of deficiency of interleukin-1 receptor antagonist (dira) kineret is contraindicated in patients with known hypersensitivity to e coli -derived proteins, kineret, or any components of the product [see hypersensitivity reactions (5.3)] . risk summary available data from retrospective studies and case reports on kineret use in pregnant women are insufficient to identify a drug associated risk of major birth defects, miscarriage, or maternal and fetal adv

Israel - English - Ministry of Health

megapharm ltd - anakinra - solution for injection - anakinra 150 mg/ml - anakinra - anakinra - kineret 100 mg solution for injection is indicated in adults for the treatment of the signs and symptoms of rheumatoid arthritis (ra) in combination with methotrexate, in patients with an inadequate response to methotrexate alone.kineret 100 mg solution for injection is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of cryopyrin-associated periodic syndromes (caps), including:- neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)- muckle-wells syndrome (mws)- familial cold autoinflammatory syndrome (fcas) kineret 100 mg solution for injection is indicated for the treatment of familial mediterranean fever (fmf). kineret 100 mg solution for injection should be given in combination with colchicine, if appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

swedish orphan biovitrum pty ltd - anakinra, quantity: 100 mg - injection, solution - excipient ingredients: polysorbate 80; sodium citrate dihydrate; water for injections; disodium edetate; sodium chloride - kineret (anakinra) is indicated: -for the treatment of active adult rheumatoid arthritis (ra) in patients who have had inadequate response to one or more other disease modifying anti rheumatic drugs (dmards). kineret should be given in combination with methotrexate. - in adult and paediatric patients aged 8 months and older with a body weight of 10 kg or above for the treatment of cryopyrin-associated periodic syndromes (caps) including neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca), muckle-wells syndrome (mws), and familial cold autoinflammatory syndrome (fcas). - for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 2 years and above who have failed to respond adequately to non-biological dmards

European Union - English - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - immunosuppressants - rheumatoid arthritis (ra)kineret is indicated in adults for the treatment of the signs and symptoms of ra in combination with methotrexate, with an inadequate response to methotrexate alone.covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml.periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret should be given in combination with colchicine, if appropriate.still’s diseasekineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of still’s disease, including systemic juvenile idiopathic arthritis (sjia) and adult-onset still’s disease (aosd), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (nsaids) or glucocorticoids.kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (dmards).

Canada - English - Health Canada

swedish orphan biovitrum ab (publ) - anakinra - solution - 150mg - anakinra 150mg - disease-modifying antirheumatic agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

swedish orphan biovitrum ltd - anakinra - solution for injection - 150mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - anakinra -

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

swedish orphan biovitrum international ab, sweden - anakinra - solution for injection - 150 mg/ml,

United States - English - NLM (National Library of Medicine)

a-s medication solutions - adalimumab (unii: fys6t7f842) (adalimumab - unii:fys6t7f842) - humira is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. humira can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (dmards). humira is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. humira can be used alone or in combination with methotrexate. humira is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. humira can be used alone or in combination with non-biologic dmards. humira is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. humira is indicated for reducing signs and symptoms and indu

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - etanercept - powder and solvent for solution for injection - 25mg